Simone Santana Viana1, Leyla Manoella Maurício Rodrigues de Lima2, Juliana Brito do Nascimento3, Carlos André Ferreira Cardoso4, Ana Carolina Dantas Rosário5, Cristiano de Queiroz Mendonça6, Osvaldo Alves de Menezes-Neto7, Rosana Cipolotti8. 1. Federal University of Sergipe, Brazil. Electronic address: simonesvi@yahoo.com.br. 2. Federal University of Sergipe, Brazil. Electronic address: ylla.lmmrl@gmail.com. 3. Federal University of Sergipe, Brazil. Electronic address: julianabriton@hotmail.com. 4. Federal University of Sergipe, Brazil. Electronic address: cafcardoso@live.com. 5. Federal University of Sergipe, Brazil. Electronic address: caroldantasr@hotmail.com. 6. Federal University of Sergipe, Brazil. Electronic address: cristiano@iocm.com.br. 7. Federal University of Sergipe, Brazil. Electronic address: oamneto28@gmail.com. 8. Federal University of Sergipe, Brazil. Electronic address: rosanaci@yahoo.com.
Abstract
BACKGROUND: The treatment for ALL has evolved in recent decades and as a result survival rates are now close to 90% in many developed countries. However, this is not the case in developing countries where survival rates are often below 35%. More than 80% of children who are affected by ALL worldwide live in developing countries. The objective of this study was to evaluate the secular trend in mortality for children with ALL living in Sergipe, a state in northeastern Brazil, and to investigate any association with variables that relate to socioeconomic status. METHOD: This study evaluated ALL patients who were less than 20 years of age and who were treated at the Dr. Osvaldo Leite Oncology Center in the capital city, Aracaju. The sample comprised two cohorts of patients from the public health service: patients treated from 1980 to 2004 (cohort A) and from 2005 to 2014 (cohort B). The findings were compared to those of patients treated in the one private service for pediatric cancer treatment available in the region, from 2005 to 2014 (cohort C). Two categories of variables were considered in this study: biological and socioeconomic. RESULTS: We analyzed 412 patients who were divided into three cohorts (cohort A: 287 patients, cohort B: 106 patients and cohort C: 19 patients). The mortality rates for the three cohorts were significantly different: 57.5% in cohort A, 45.3% in cohort B and 26.3% in cohort C (p=0.006). Mortality during induction in cohort B was 22.6%, while in cohort C no deaths occurred during this phase (p=0.041). Patients living in rural areas had higher mortality rates (p=0.036). CONCLUSIONS: The reduction in deaths from infection during induction seems to be the starting point for improving the chances for children and adolescents with ALL anywhere in the world.
BACKGROUND: The treatment for ALL has evolved in recent decades and as a result survival rates are now close to 90% in many developed countries. However, this is not the case in developing countries where survival rates are often below 35%. More than 80% of children who are affected by ALL worldwide live in developing countries. The objective of this study was to evaluate the secular trend in mortality for children with ALL living in Sergipe, a state in northeastern Brazil, and to investigate any association with variables that relate to socioeconomic status. METHOD: This study evaluated ALL patients who were less than 20 years of age and who were treated at the Dr. Osvaldo Leite Oncology Center in the capital city, Aracaju. The sample comprised two cohorts of patients from the public health service: patients treated from 1980 to 2004 (cohort A) and from 2005 to 2014 (cohort B). The findings were compared to those of patients treated in the one private service for pediatric cancer treatment available in the region, from 2005 to 2014 (cohort C). Two categories of variables were considered in this study: biological and socioeconomic. RESULTS: We analyzed 412 patients who were divided into three cohorts (cohort A: 287 patients, cohort B: 106 patients and cohort C: 19 patients). The mortality rates for the three cohorts were significantly different: 57.5% in cohort A, 45.3% in cohort B and 26.3% in cohort C (p=0.006). Mortality during induction in cohort B was 22.6%, while in cohort C no deaths occurred during this phase (p=0.041). Patients living in rural areas had higher mortality rates (p=0.036). CONCLUSIONS: The reduction in deaths from infection during induction seems to be the starting point for improving the chances for children and adolescents with ALL anywhere in the world.